Next round of KRAS drugs stretch for their 4-minute mile in the footsteps of Amgen and Mirati

[{"selector":"#anim-aec97ad0-0eb7-4056-a09f-e319dc6773e7","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ddcec2bb-a3b7-466a-b9f6-dcc698518c00","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Amgen and Mirati Therapeutics are competing for first-to-market advantage with their KRAS inhibitors.

[{"selector":"#anim-d115c7bc-3b8e-452d-a8df-de4d92979faa","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. Large companies like Eli Lilly and Roche's Genentech are also entering the KRAS inhibitor scene.

[{"selector":"#anim-019406ef-9634-44f0-8cd2-feed58e72352","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. The goal is to outperform Amgen's Lumakras and Mirati's Krazati in side effects and combination regimens.

[{"selector":"#anim-2a01f19c-308c-4303-96bc-7e9942c56f59","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. KRAS mutations are the most frequent oncogenic alterations in humans, with potential for multiple treatment options.

[{"selector":"#anim-ce44949e-9134-427a-b006-b5bef063ecab","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. Drugging the KRAS mutation was once thought impossible, but various companies now show preclinical and early clinical success.

[{"selector":"#anim-554f8b44-be08-43ef-a4d3-cef23bba41e3","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. Genentech's divarasib showed promising results in a small phase 1b study for colorectal cancer.

[{"selector":"#anim-a8a7c4d2-f04d-4efc-aa1c-8de9dfd33f55","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. Lilly's LY3537982 demonstrated preliminary efficacy across multiple tumor types in a phase 1 study.

[{"selector":"#anim-8009edce-58bc-4230-8453-913010e6ad93","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. Smaller companies are targeting other KRAS mutations, such as G12D and G13C.

[{"selector":"#anim-0f954cdf-2d0e-41f1-b0b2-3011a61e53e7","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. Dr. Hong of MD Anderson Cancer Center suggests that first-line setting may be possible for KRAS-mutated cancers.

[{"selector":"#anim-99a09875-aa16-48c7-892a-a5734d4ea84c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Genentech's Fuchs hopes KRAS inhibitors can make a significant impact in pancreatic cancer treatment.

[{"selector":"#anim-013683c0-9396-48ea-a22f-a33a363de091","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-d57785c8-2938-42b2-a115-0b44970aafe4","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more